The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.

MLA

Agnieszka Czarniecka, et al. “The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.” PLoS ONE, vol. 10, no. 7, Jan. 2015, p. e0132821. EBSCOhost, https://doi.org/10.1371/journal.pone.0132821.

APA

Agnieszka Czarniecka, Monika Kowal, Dagmara Rusinek, Jolanta Krajewska, Michal Jarzab, Ewa Stobiecka, Ewa Chmielik, Ewa Zembala-Nozynska, Stanislaw Poltorak, Aleksander Sacher, Adam Maciejewski, Jadwiga Zebracka-Gala, Dariusz Lange, Malgorzata Oczko-Wojciechowska, Daria Handkiewicz-Junak, & Barbara Jarzab. (2015). The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors. PLoS ONE, 10(7), e0132821. https://doi.org/10.1371/journal.pone.0132821

Chicago

Agnieszka Czarniecka, Monika Kowal, Dagmara Rusinek, Jolanta Krajewska, Michal Jarzab, Ewa Stobiecka, Ewa Chmielik, et al. 2015. “The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.” PLoS ONE 10 (7): e0132821. doi:10.1371/journal.pone.0132821.